Pre-Made Aldafermin Biosimilar, Recombinant Protein targeting FGFR4: Recombinant therapeutic protein targeting CD334/JTK2/TKF for drug discovery and mechanism of action (MOA) research

Pre-Made Aldafermin Biosimilar, Recombinant Protein targeting FGFR4: Recombinant therapeutic protein targeting CD334/JTK2/TKF is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Non-alcoholic steatohepatitis (NASH) is characterized by hepatic steatosis, inflammation, and injury, and is associated with an increased risk of liver transplantation and death. A Aldafermin, an engineered analog of fibroblast growth factor 19, inhibits bile acid synthesis and regulates metabolic homeostasis in patients with non-alcoholic steatohepatitis.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-727-1mg	1mg	3090
GMP-Bios-INN-727-10mg	10mg	Inquiry
GMP-Bios-INN-727-100mg	100mg	Inquiry
GMP-Bios-INN-727-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Aldafermin Biosimilar, Recombinant Protein targeting FGFR4: Recombinant therapeutic protein targeting CD334/JTK2/TKF
INN Name	Aldafermin
Target	FGFR4
Format	Recombinant Protein
Derivation	human
Species Reactivity	human
CH1 Isotype	FGF19 (fibroblast growth factor 19) 5- 194
VD LC	FGF19 (fibroblast growth factor 19) 5- 194
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	NGM Biopharmaceuticals, Inc. (South San Francisco CA USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0